Sign in →

Test Code OXAZS Oxazepam, Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (Serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Secondary ID

623016

Useful For

Assessing compliance

 

Monitoring for appropriate therapeutic level

 

Assessing oxazepam toxicity

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Oxazepam, S

Specimen Type

Serum Red

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Clinical Information

Oxazepam is US Food and Drug Administration-approved for the management of anxiety disorders and is used to relieve anxiety, including that caused by alcohol withdrawal (symptoms may develop in people who stop drinking alcohol after drinking large amounts for an extended time). Oxazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation.

 

Oxazepam is metabolized by glucuronidation and has an intermediate half-life (approximately 4-16 hours) compared to other benzodiazepines. Common adverse effects include dizziness, headaches, somnolence and vertigo.

Reference Values

Therapeutic concentrations

Oxazepam: 200-1500 ng/mL

 

Cutoff concentrations by liquid chromatography tandem mass spectrometry:

Oxazepam: 10 ng/mL

Interpretation

Suggested therapeutic serum concentrations have been reported for oxazepam between 200 and 1500 ng/mL.

Cautions

No significant cautionary statements

Clinical Reference

1. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43

2. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018:51(1-02):9-62

3. Baselt RC. Disposition of Toxic Drugs and Chemical in Man. 12th ed. Biomedical Publications; 2020

Method Description

The internal standard mixture containing chlordiazepoxide-d5, diazepam-d5, nordiazepam-d5, oxazepam-d5, and temazepam-d5 is added to serum samples, mixed and centrifuged. The supernatant is diluted and injected on a liquid chromatography tandem mass spectrometer.(Unpublished Mayo method)

Day(s) Performed

Monday, Wednesday

Report Available

3 to 7 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80299

LOINC Code Information

Test ID Test Order Name Order LOINC Value
OXAZS Oxazepam, S 3886-9

 

Result ID Test Result Name Result LOINC Value
623016 Oxazepam 3886-9